We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Toxicity of Intrathecally Administered Pancreatic Dornase

Richard H. Parker, MD; W. Dean Wilcox, MD; Thomas S. Dietrich, MD
JAMA. 1965;192(2):169-171. doi:10.1001/jama.1965.03080150099032.
Text Size: A A A
Published online

DEATH AND MORBIDITY from pyogenic meningitis have been dramatically reduced since the discovery of antimicrobial agents. Yet, 5% to 25% of patients with this disease die, and 5% to 25% who survive have neurological complications, in spite of seemingly appropriate antimicrobial therapy.1 Since these fatalities and complications may be related to the presence of extensive inflammatory exudate over the meninges, enzymatic debridement has been suggested as an adjunct to therapy.2 Virtual absence of antigenicity distinguishes pancreatic dornase from deoxyribonuclease (DNA-ase) produced by streptococci. Thus, pancreatic dornase was selected for intrathecal injection, as a means of liquefying the exudate from pyogenic meningitis. In the few reported cases, there has been no mention of toxicity from the intrathecal administration of pancreatic dornase.2,3

This case is reported because fever, nuchal rigidity, and elevated cerebrospinal-fluid-protein levels occurred after the intrathecal injection of pancreatic dornase. Reporting of this single case is further


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.